SDG 3 and 17 in motion

A PARTNERSHIP OF PARTNERSHIPS TO MOBILISE POLITICAL ACTION AND ENSURE HEALTHY AND SUSTAINABLE ECONOMIES BEYOND 2030
WHO WE ARE

The G20 Health & Development Partnership (G20HDP) is an advocacy organisation that aims to ensure that G20 countries coordinate their health innovation strategies to tackle the growing burden of communicable and non-communicable diseases globally, to promote the delivery of the United Nations Sustainable Development Goals (SDGs) with a focus on SDG 3 “health and well-being for all”.

The G20HDP emerged as an informal coalition of like-minded organisations during the G20 Presidency in Germany in 2017, building on the objectives of SDG 17, “strengthening partnerships”. Our 22 partner organisations from across different sectors include product development partnerships; not-for-profit organisations; international organisations; public-private partnerships; health tech start-up’s; the pharmaceutical industry; research institutions and academia. The Partnership is supported by a network of high profile Global Ambassadors.

“G20 heads of government and finance ministers must play a central role in tackling the growing disease burden in low- and middle-income countries and high-income countries. The G20HDP is engaging with leaders at the highest level to bring about this policy shift. A strong economy can only be built by a healthy nation!”

Alan Donnelly,
Convenor and Chair of the G20HDP
Since 2017, the G20HDP has successfully engaged with the G20 presidencies of Germany, Argentina, Japan and the Kingdom of Saudi Arabia to elevate health on the political agendas of G20 governments, specifically among G20 Heads of State, and ministers of health and finance. The G20HDP believes in the strong linkage of healthy nations and sustainable economies and continues to position health as a key factor determining the future of global economies, by breaking existing silos in the health space.

In 2018, the G20HDP launched the first Health20 (H20) summit on the side-lines of the World Health Assembly in Geneva. In 2019, the G20HDP organised the second successful summit in Tokyo involving wider participation from the public and private sectors, including economists from the G20. Each year, the recommendations by G20HDP partners and from the H20 are compiled into a “Call to Action”, which is reflected in G20 Leaders, health ministers and finance ministers’ Declarations.

The G20HDP report “Healthy Nations-Sustainable Economies“, launched by Lord Jim O’Neill and members of the UK Parliament in 2019, was submitted to G20 health and finance ministers ahead of their first joint meeting. The report highlighted the impact of the world’s deadliest diseases and pandemics on national economies and how sustainable and blended finance mechanisms can help to tackle these challenges overtime.

With the rising challenges faced by the COVID-19 pandemic, the G20HDP seeks to set in motion sustainable ways of funding for innovation and access to help fund the diagnostic tests, treatments, vaccines, medical supplies and delivery systems that are so urgently needed. Investment in health innovation and delivery produces significant returns, including improvements in sustainable growth.
THE COVID-19 CRISIS

During the G20 Presidency of the Kingdom of Saudi Arabia, the G20HDP was granted observer status in official G20 meetings and supported the Presidency with recommendations and expert insights. To meet the short and long-term challenges of COVID-19 and to suggest concrete solutions that can only be achieved through partnerships, the G20HDP launched the H20 Digital Dialogue Series, bringing together G20HDP partners and senior ministers, policymakers and representatives of multilateral organisations.

The G20HDP is also supportive of and is proactively engaging in the Global Coronavirus Response (ACT-Accelerator) launched by the European Commission on 4th May 2020. This initiative jointly coordinates and promotes the development and procurement of tests, vaccines and treatments worldwide.

Our distinguished H20 Digital Dialogue Series Keynote Speakers

Dr Tedros Adhanom Ghebreyesus
Assistant Director-General
Antimicrobial Resistance
World Health Organization

H.E. Dr Bandar M. H. Hajjar
President of the Islamic Development Bank

Margaritis Schinas
Vice President
European Commission

Dr Rafael Mariano Grossi
Director General of the International Atomic Energy Agency

H.E. Dr Christoph Heusgen
Permanent Representative of Germany to the United Nations Security Council

Jens Spahn
Federal Minister for Health Germany

Dr Werner Hoyer
President, European Investment Bank

Dr Hanan Balkhy
Assistant Director-General
Antimicrobial Resistance
World Health Organization
THE G20HDP’s OBJECTIVES

The G20HDP highlights the underinvestment in tackling the global disease burden. It impairs growth and economic performance, presenting major long-term challenges for public budgets. To date, there are over US$200 trillion in Capital Markets. If we spend just 0.5% on health, we can close the SDG3 gap by 2030. New models of Impact Investment and Blended Financing initiatives in collaboration with governments, philanthropic organisations, multilateral development banks and private sector investors can significantly close the existing funding gap in achieving SDG3. Based on the experiences of dealing with previous pandemics and currently COVID-19, the G20HDP aims to raise awareness that the future of health financing should no longer be treated as disaster relief and that innovative models should be promoted and put to the attention of G20 health and finance Ministers and G20 Heads of State.

As the G20 continue to focus on areas of global health security and health system strengthening, including the response to COVID-19 and the rise of silent pandemics such as antimicrobial resistance and non-communicable diseases, the G20HDP will seek to add value to these areas and drive political support for both the G7 Presidency of the United Kingdom and the G20 Presidency of Italy in 2021. Socio-economic and environmental impacts, the value of technological disruptions to drive forward a new era of E-health and the role of patients and health workers will form the central tenet of the G20HDPs work in mobilising political support to achieve Universal Health Coverage by 2030.
<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mr Elmar Brok</td>
<td>Former Member of the European Parliament, CDU Federal Board Member, Aspen Senior Fellow</td>
</tr>
<tr>
<td>Prof Rifat Atun</td>
<td>Professor of Global Health Systems, Harvard University</td>
</tr>
<tr>
<td>Dr Hayat Sindi</td>
<td>Senior Adviser to H.E. the President for Science, Technology and Innovation, Islamic Development Bank</td>
</tr>
<tr>
<td>Ms Angela Eagle MP</td>
<td>Member of the UK House of Commons</td>
</tr>
<tr>
<td>Rt Hon. the Lord Jack Cunningham of Felling DL</td>
<td>Member of the UK House of Lords</td>
</tr>
<tr>
<td>Dr Abdulelah Alhawsawi</td>
<td>Former Director General, Saudi Patient Safety Centre</td>
</tr>
<tr>
<td>Mr Willo Brock</td>
<td>Senior Vice President for External Affairs, TB Alliance</td>
</tr>
<tr>
<td>Mr Guanyu Zhou</td>
<td>Championship Driver, FIA Formula 2</td>
</tr>
<tr>
<td>Professor Dr Abdullah Aldahmarsh</td>
<td>Director General, Prince Naif Bin Abdulaziz Health Research Centre at King Saud University and Acting Dean, Alfarabi Medical College, Riyadh</td>
</tr>
<tr>
<td>Mr Mishaal Fahd K Al-Sudairy</td>
<td>Board Member, Saudi Aviation Club</td>
</tr>
<tr>
<td>Mr Ajay Kumar Bramdeo</td>
<td>Former Ambassador and Permanent Observer of the African Union to the United Nations Office at Geneva</td>
</tr>
<tr>
<td>Mr Philippe Fauchet OBE</td>
<td>Founder, Mirasense Partners</td>
</tr>
<tr>
<td>Dr Ricardo Baptista Leite MP</td>
<td>Member of the Portuguese Parliament; Founder and President, UNITE</td>
</tr>
<tr>
<td>Ms Jamie Bay Nishi</td>
<td>Director, Global Health Technologies Coalition</td>
</tr>
<tr>
<td>Dr Harald Nusser</td>
<td>Global Head, Novartis Social Business</td>
</tr>
<tr>
<td>Dr Monika Puri</td>
<td>Head, Institutional Relations, Roche</td>
</tr>
<tr>
<td>Mr Paul Rübig</td>
<td>Former Member of the European Parliament</td>
</tr>
</tbody>
</table>
Our Partners

- BD
- Bugworks
- CEPI
- Columbia University
- FIND
- GHIT Fund
- Gramin Health Care
- GHTC
- IFPMA
- Johnson & Johnson
- MMV
- mPedigree
- Medicines Patent Pool
- Mitsubishi UFJ Research and Consulting
- Novartis
- PATH
- RLDatix
- Roche
- TB Alliance
- Unitaid
- WifOR Institute
Contact the team

Alan Donnelly
Convenor and Chair

Hatice Küçük
Executive Director

Joseph Dancey
Senior Counsel

Jack Nagy
Policy Advisor

THE G20 HEALTH AND DEVELOPMENT PARTNERSHIP

26–27 BEDFORD SQUARE, LONDON, WC1B 3HP

office@ssdhub.org

ssdhub.org

@G20Partnership

G20 Health and Development Partnership

An initiative supported by Sovereign Sustainability and Development that provides the Secretariat of G20HDP